Cilengitide

N/A

Report date: 2024/07/05 11:15:06
NME

Base Information

Drug NameCilengitide
Drug Alias Namecilengitide西仑吉肽cilengitidacilengitidumNSC-707544 +[7] 
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-V/beta-5 antagonistsIntegrin alpha-V/beta-3 antagonists
TargetsIntegrin alpha-V/beta-5Integrin alpha-V/beta-3
Therapy Area/IndicationsCNS Embryonal TumorSolid tumoursAngioimmunoblastic T-cell Lymphoma +[64] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[14] 
CombinationsNo
Global Highest StatusDiscontinued (Phase 3 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMerck Serono
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEmd Serono IncMartin-Luther-Universitat Halle-WittenbergIndiana University School Of Medicine +[8] 
Active IndicationsN/A
Inactive IndicationsCNS Embryonal TumorSolid tumoursAngioimmunoblastic T-cell Lymphoma +[64] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG